<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="systematic-review"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Digit Health</journal-id><journal-id journal-id-type="iso-abbrev">Front Digit Health</journal-id><journal-id journal-id-type="publisher-id">Front. Digit. Health</journal-id><journal-title-group><journal-title>Frontiers in Digital Health</journal-title></journal-title-group><issn pub-type="epub">2673-253X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400544</article-id><article-id pub-id-type="pmc">PMC12092381</article-id><article-id pub-id-type="doi">10.3389/fdgth.2025.1584764</article-id><article-categories><subj-group subj-group-type="heading"><subject>Digital Health</subject><subj-group><subject>Systematic Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Effectiveness of mobile health in symptom management of prostate cancer patients: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Hai Shan</given-names></name><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/2988365/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Hua</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Hai Hang</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yuan</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Nu</given-names></name><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Ya Mei</given-names></name><xref rid="cor1" ref-type="corresp">*</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff><institution>Department of Urology, The Seventh Affiliated Hospital of Sun Yat-sen University</institution>, <addr-line>Shenzhen</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Avishek Choudhury, West Virginia University, United States</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Tanmoy Sarkar Pias, Virginia Tech, United States</p><p>Hao Chen, Xiamen University of Technology, China</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Hai Shan Chen <email>chenhaishan@sysush.com</email> Ya Mei Li <email>liyamei@sysush.com</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>7</volume><elocation-id>1584764</elocation-id><history>
<date date-type="received"><day>02</day><month>3</month><year>2025</year></date>
<date date-type="accepted"><day>11</day><month>4</month><year>2025</year></date>
</history><permissions><copyright-statement>&#x000a9; 2025 Chen, He, Lin, Zhang, Li and Li.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Chen, He, Lin, Zhang, Li and Li</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background</title><p>Mobile health (mHealth) is an accessible strategy to deliver health information and is becoming increasingly popular as a form of follow-up among medical staff. However, the effects of mobile health on the physical and mental health outcomes of patients with prostate cancer after discharge from the hospital remain unclear. This meta-analysis evaluated the current evidence regarding the effects of mHealth interventions on the outcomes of patients with prostate cancer.</p></sec><sec><title>Methods</title><p>Four databases (PubMed, Cochrane Central electronic database, EMBASE, and Web of Science) were searched from inception to 8 November 2024 for randomized controlled trials (RCTs) comparing the effects of mobile health vs. usual care on the outcomes of patients with prostate cancer. Pooled outcome measures were determined using random effects models.</p></sec><sec><title>Results</title><p>In total, 11 RCTs, including 1,368 patients, met the criteria for inclusion in this meta-analysis. The meta-analysis revealed a significant effect of mHealth interventions on long-term bowel function outcomes (standard mean difference&#x02009;=&#x02009;0.19, 95% confidence interval&#x02009;=&#x02009;0.01&#x02013;0.37, <italic>P</italic>&#x02009;=&#x02009;0.04, I<sup>2</sup>&#x02009;=&#x02009;0.00%) compared with the usual standard care or no mHealth. However, no significant differences were observed in the following outcomes: short-term and long-term effects on anxiety, depression, self-efficacy, psychological distress, and urinary and hormonal function, and short-term effects on bowel function.</p></sec><sec><title>Conclusions</title><p>mHealth interventions can significantly improve long-term bowel function outcomes. However, more research is needed to confirm other physical and mental health outcomes.</p></sec><sec><title>Systematic Review Registration</title><p><uri xlink:href="https://www.crd.york.ac.uk/prospero/">https://www.crd.york.ac.uk/prospero/</uri>, PROSPERO (CRD420250651320).</p></sec></abstract><kwd-group><kwd>prostate cancer</kwd><kwd>mobile health (mHealth)</kwd><kwd>symptom management</kwd><kwd>long-term effects</kwd><kwd>short-term effects</kwd><kwd>meta-analysis</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the Department of Urology, Seventh Affiliated Hospital of Sun Yat-sen University.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="5"/><equation-count count="0"/><ref-count count="65"/><page-count count="14"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Human Factors and Digital Health</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Prostate cancer (PC) is the second-most prevalent cancer in men worldwide (<xref rid="B1" ref-type="bibr">1</xref>). GLOBOCAN 2020 estimates reported 1,414,259 new cases of prostate cancer globally in 2020, with a higher prevalence in developed countries (<xref rid="B2" ref-type="bibr">2</xref>). During active treatment (prostatectomy, chemotherapy, radiotherapy, and/or hormone therapy) and the years after (survivorship), many patients experience symptom distress, including physical (urinary symptoms, bowel symptoms, sexual dysfunction, hormonal imbalance symptoms, etc.), psychological (anxiety, depression, etc.), and social aspects (stigma, social alienation, etc.), which can negatively affect quality of life (QOL) (<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>). Studies have shown that the incidence of urinary incontinence among localized prostate cancer was 4%&#x02013;31%, the incidence of fecal incontinence was 4%&#x02013;10%, and the incidence of sexual dysfunction was 11%&#x02013;87%. These symptoms can even last as long as 10&#x02005;years (<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B9" ref-type="bibr">9</xref>). Compared to men with localized disease, men with advanced prostate cancer experience greater pain and fatigue, higher levels of psychosocial distress, increased risk of suicide, and poorer health-related quality of life (<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>). Many of these symptoms persist for years, even after treatment is completed. As a result, many patients suffer from socioeconomic loss, resulting in significant life changes. Therefore, a strategy to reduce symptom distress during treatment or after discharge is of great clinical value.</p><p>Mobile health (mHealth) is an accessible strategy for delivering health information and has been widely used during the COVID-19 pandemic (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). A recent meta-analysis revealed that mHealth interventions may provide an acceptable and feasible strategy to deliver continuity of health support to patients between medical appointments (<xref rid="B15" ref-type="bibr">15</xref>). Moreover, these interventions offer a convenient way to support self-management of cancer-related symptoms (<xref rid="B16" ref-type="bibr">16</xref>). Whether an individual receives treatment for PC upon diagnosis or is actively monitored over time, mHealth applications offer great opportunities for men to receive personalized, timely, high-quality, and evidence-based care (<xref rid="B17" ref-type="bibr">17</xref>). However, patients with prostate cancer have multiple and complex symptoms during and after treatment, with a long recovery period. After discharge, patients still need continuous and comprehensive interventions and nursing for rehabilitation training, prevention of complications, psychology, and other aspects (<xref rid="B18" ref-type="bibr">18</xref>). Therefore, mHealth interventions offer patients with PC an alternative form of medical care through a variety of communication technologies, including telephone, mail, remote video, or mobile applications, to treat patients at a distance.</p><p>However, the short-term and long-term effects of remote interventions on symptom management in patients with PC are unclear, and less attention has been paid to the long-term effects of the interventions. A newly published scoping review has shown that the current application of mHealth interventions in PC survivorship care pathways remains poor, with 10 mHealth apps identified and only one still in use, and the long-term effects of these apps are currently unknown (<xref rid="B18" ref-type="bibr">18</xref>). This research highlights the benefits of mHealth among patients with PC and shows long-term (12-month) improvements in urinary irritation, bowel function, hormonal function, and depression scores (<xref rid="B19" ref-type="bibr">19</xref>). However, a randomized controlled trial from Australia revealed that 12&#x02005;months of telephone intervention was not accompanied by overall improvements in QOL or psychological distress (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>A literature review found that most studies on the impact of mHealth on symptom management for patients with prostate cancer have evaluated the long-term effects of the intervention by following up patients for 3&#x02005;months after the intervention (<xref rid="B20" ref-type="bibr">20</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>). Therefore, this study focused on the short- and long-term effects of the intervention at a node of 3&#x02005;months. Given these findings, it is necessary to update meta-analyses to comprehensively analyze the impact of mHealth interventions on symptom management of patients with PC.</p></sec><sec sec-type="methods" id="s2"><label>2</label><title>Methods</title><sec id="s2a"><label>2.1</label><title>Protocol registration</title><p>This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) guidelines (<xref rid="B23" ref-type="bibr">23</xref>). The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (Registration ID: CRD420250651320; available at: <ext-link xlink:href="https://www.crd.york.ac.uk/prospero/" ext-link-type="uri">https://www.crd.york.ac.uk/prospero/</ext-link>).</p></sec><sec id="s2b"><label>2.2</label><title>Study selection</title><p>The PubMed, Cochrane Central electronic database, EMBASE, and Web of Science were searched from inception to 8 November 2024 using a series of keywords related to mobile health and prostate cancer. The details of the search strategy are presented in the <xref rid="s11" ref-type="sec">Supplementary Appendix</xref>. To avoid missing any relevant studies, manual searches of the reference lists of all included articles were also performed, as were searches of the reference lists of previous related meta-analyses or systematic reviews.</p><p>The inclusion criteria for studies were as follows: (1) population: adults (age&#x02009;&#x0003e;&#x02009;18&#x02005;years) with a prostate cancer diagnosis who were undergoing or completed active prostate cancer treatment (surgery, chemotherapy, and/or radiotherapy); (2) intervention: mHealth interventions including but not limited to smartphone apps, SMS, or wearable devices targeting symptom monitoring or self-management; (3) control group comprised of those receiving the usual care (e.g., standard follow-up) or non-digital interventions (e.g., paper diaries); (4) primary outcomes: mental (depression, anxiety, and distress) or physical (urinary function, sexual function, bowel function, and hormonal function) health outcomes based on standardized scales with a secondary outcome of quality of life; (5) study design: randomized controlled trials (RCTs). This meta-analysis focused on the short-term and long-term effects of the intervention at the node of 3&#x02005;months. The short-term effect was measured after the end of the intervention, and the measured outcome indicators were followed up for &#x02264;3&#x02005;months. The long-term effect was measured after the end of the intervention, and the measured outcome indicators were followed up for &#x0003e;3&#x02005;months (we selected the longest time point as the data outcome).</p><p>Studies were excluded from this meta-analysis according to the following exclusion criteria: (1) publication in any language other than English or (2) presentation of incomplete data or duplicated data.</p><p>EndNote X9 (Clarivate Analytics, <ext-link xlink:href="https://www.endnote.com" ext-link-type="uri">https://www.endnote.com</ext-link>) was used to manage references. Two authors (HSC and HH) independently examined titles and abstracts to select eligible trials. In cases of discrepancies between the two authors' selections, a third author (YML) was consulted to resolve the differences. Full-text articles were then retrieved and reviewed using the same method to determine which trials met the inclusion criteria for this study.</p></sec><sec id="s2c"><label>2.3</label><title>Data extraction</title><p>Two authors (HH and HHL) independently extracted data from the included trials using a data extraction table that included general information (title, first author, publication date, and study location), trial characteristics (sample size, method of randomization, allocation, blinding method, incomplete outcomes data, selective reporting, and other), subject characteristics (country, neoplasm staging, treatment condition, and age), intervention (type of intervention, intervention and follow-up durations, frequency of mHealth use, intervener, and theoretical framework), and outcomes (outcome measures). Discrepancies between authors were resolved through consultation with a third author (HSC).</p></sec><sec id="s2d"><label>2.4</label><title>Risk of bias assessment</title><p>In this study, two reviewers (HSC and HH) assessed the quality of the included studies using the Risk of Bias 2 (RoB 2) tool, as recommended by the Cochrane Handbook (<xref rid="B24" ref-type="bibr">24</xref>). This tool evaluates the risk of bias in five domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in the measurement of the outcome, and bias in the selection of the reported result. An overall risk of bias assessment was also conducted for each study. Disagreements with respect to the methodological quality were resolved by discussion and mutual consultation (YML).</p></sec><sec id="s2e"><label>2.5</label><title>Statistical analysis</title><p>The effects of mHealth on the outcomes of patients with PC were evaluated on the basis of the included studies. Continuous variables were evaluated and combined using mean difference (MD) when units of measurement were consistent across studies or could be converted to a common scale. When the units could not be directly compared or converted, the standardized mean difference (SMD) was used (<xref rid="B24" ref-type="bibr">24</xref>). The statistical parameter I<sup>2</sup> was used to examine the heterogeneity of the effect sizes, with values higher than 50% indicating substantial heterogeneity (<xref rid="B24" ref-type="bibr">24</xref>). In this study, considering the existence of clinical heterogeneity (e.g., mode of intervention, participant characteristics), we employed the DerSimonian and Laird random effects model for our meta-analysis (<xref rid="B24" ref-type="bibr">24</xref>). A sensitivity analysis was conducted by removing the RCTs that included interventions that relied entirely on mHealth, those that included interventions that were delivered by peer support volunteers, or those that included a theory or framework referenced across the studies to detect the stability of the results. If the number of included studies for the outcome indicators was more than 10, a funnel plot and Egger&#x02019;s test were used to detect publication bias. The level of statistical significance was set at <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and all statistical tests were two-sided. Statistical analyses were performed using STATA version 17.0 (Stata Corp LP, College Station, TX, USA).</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><sec id="s3a"><label>3.1</label><title>Study identification and selection</title><p>The initial search identified 6,302 articles. After screening of titles and abstracts, 6,273 articles were excluded, including 1,507 duplicates, and 4,766 articles that did not meet the inclusion criteria. The full texts of 29 articles were reviewed, and 18 of these articles were excluded due to incomplete data (<italic>N</italic>&#x02009;=&#x02009;6) (<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>), content that did not conform to our study (PICOS) (<italic>N</italic>&#x02009;=&#x02009;11) (<xref rid="B30" ref-type="bibr">30</xref>&#x02013;<xref rid="B40" ref-type="bibr">40</xref>), or being a conference abstract (<italic>N</italic>&#x02009;=&#x02009;1) (<xref rid="B37" ref-type="bibr">37</xref>). Finally, 11 RCTs were included in the present meta-analysis (<xref rid="F1" ref-type="fig">Figure&#x000a0;1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Inclusion screening flow chart.</p></caption><graphic xlink:href="fdgth-07-1584764-g001" position="float"/></fig><p>The characteristics of the included RCTs are summarized in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>. The 11 RCTs included two studies (18%) conducted in Australia, Canada, the UK, the USA, and Korea, and one (9%) study conducted in Germany. All RCTs were published in English and conducted between 2013 and 2022. A total of 1,368 patients diagnosed with prostate cancer were included. Among the 11 included RCTs, the study of Galv&#x000e3;o et al. (<xref rid="B20" ref-type="bibr">20</xref>) had the largest sample size with 463 individuals. Except for two RCTs, which used an Internet intervention, all other mHealth interventions were performed over the telephone. Interventions ranged from 6&#x02005;weeks to 6&#x02005;months in duration, and the studies were delivered by professional technical personnel (including clinical psychologists, clinicians, physicians, clinical nutritionists, nurses, and research assistants) (<italic>n</italic>&#x02009;=&#x02009;10) and peer support volunteers (<italic>n</italic>&#x02009;=&#x02009;1). Most interventions were delivered by health and social care professionals, and only one relied entirely on mHealth. One theory or framework was referenced across studies (<xref rid="B21" ref-type="bibr">21</xref>). The control group received the usual care, ethical care, guidelines for patients with prostate cancer, or health promotion.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of the included articles.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="3" colspan="1">Study</th><th valign="top" align="center" rowspan="3" colspan="1">Country</th><th valign="top" align="center" rowspan="3" colspan="1">Design</th><th valign="top" align="center" rowspan="3" colspan="1">Neoplasm staging</th><th valign="top" align="center" rowspan="3" colspan="1">Treatment condition</th><th valign="top" align="center" rowspan="2" colspan="2">No. of participants</th><th valign="top" align="center" colspan="2" rowspan="1">Mean age&#x02009;&#x000b1;&#x02009;SD</th><th valign="top" align="center" rowspan="2" colspan="2">Type of intervention</th><th valign="top" align="center" rowspan="3" colspan="1">Theory or 
framework</th><th valign="top" align="center" rowspan="3" colspan="1">Outcome</th></tr><tr><th valign="top" align="center" colspan="2" rowspan="1">(years)</th></tr><tr><th valign="top" align="center" colspan="2" rowspan="1">Trial control</th><th valign="top" align="center" colspan="2" rowspan="1">Trial control</th><th valign="top" align="center" colspan="2" rowspan="1">Trial control</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="5" colspan="1">Davis et al. (<xref rid="B41" ref-type="bibr">41</xref>)</td><td valign="top" align="left" rowspan="5" colspan="1">USA</td><td valign="top" align="left" rowspan="5" colspan="1">RCT, two arms</td><td valign="top" align="left" rowspan="5" colspan="1">Early-stage PC survivors</td><td valign="top" align="left" rowspan="5" colspan="1">RP, RT, ADT, 
watchful waiting</td><td valign="top" align="center" rowspan="5" colspan="1">49</td><td valign="top" align="center" rowspan="5" colspan="1">45</td><td valign="top" align="center" rowspan="5" colspan="1">61.9&#x02009;&#x000b1;&#x02009;7.0</td><td valign="top" align="center" rowspan="5" colspan="1">62.0&#x02009;&#x000b1;&#x02009;8.1</td><td valign="top" align="left" rowspan="1" colspan="1">Form: telephone</td><td valign="top" align="left" rowspan="5" colspan="1">Usual care</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="5" colspan="1">General health-related quality of life (HRQOL), cancer-specific HRQOL, prostate cancer&#x02013;specific HRQOL, Post-visit ratings (PVR)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: symptom monitoring plus feedback</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: &#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: three telephone interviews</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: research assistant (RA)</td></tr><tr><td valign="top" align="left" rowspan="6" colspan="1">Hunter et al. (<xref rid="B42" ref-type="bibr">42</xref>)</td><td valign="top" align="left" rowspan="6" colspan="1">UK</td><td valign="top" align="left" rowspan="6" colspan="1">RCT, two arms</td><td valign="top" align="left" rowspan="6" colspan="1">Localized (50%), locally 
advanced (19%), and 
metastatic cancer (31%)</td><td valign="top" align="left" rowspan="6" colspan="1">ADT</td><td valign="top" align="center" rowspan="6" colspan="1">33</td><td valign="top" align="center" rowspan="6" colspan="1">35</td><td valign="top" align="center" rowspan="6" colspan="1">67.97&#x02009;&#x000b1;&#x02009;7.65</td><td valign="top" align="center" rowspan="6" colspan="1">69.71&#x02009;&#x000b1;&#x02009;7.9</td><td valign="top" align="left" rowspan="2" colspan="1">Form: a booklet, CD, and telephone contact</td><td valign="top" align="left" rowspan="6" colspan="1">Usual care</td><td valign="top" align="left" rowspan="6" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Hot flushes and night sweats (HFNS)-Hot Flush Rating Scale</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">(HFRS), Hospital Anxiety and Depression Scale (HADS), health-related quality of life</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: guided self-help cognitive behavioural therapy (CBT)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: &#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: 6 weeks</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: clinical psychologist (ES)</td></tr><tr><td valign="top" align="left" rowspan="10" colspan="1">Chambers et al. (<xref rid="B22" ref-type="bibr">22</xref>)</td><td valign="top" align="left" rowspan="10" colspan="1">Australia</td><td valign="top" align="left" rowspan="10" colspan="1">RCT, three arms</td><td valign="top" align="left" rowspan="10" colspan="1">Localized prostate 
cancer</td><td valign="top" align="left" rowspan="10" colspan="1">RP</td><td valign="top" align="center" rowspan="5" colspan="1">61</td><td valign="top" align="center" rowspan="5" colspan="1">64</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Form: telephone</td><td valign="top" align="left" rowspan="5" colspan="1">Usual care</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="10" colspan="1">Sexual function, sexuality needs, sexual self-confidence, masculine self-esteem, marital satisfaction or intimacy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: nurse counseling</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: &#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: &#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: prostate cancer nurse</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">64</td><td valign="top" align="left" rowspan="5" colspan="1">64</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Form: telephone</td><td valign="top" align="left" rowspan="5" colspan="1">Usual care</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: peer support</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: &#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: &#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: peer support volunteers (Peers)</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">Lambert et al. (<xref rid="B43" ref-type="bibr">43</xref>)</td><td valign="top" align="left" rowspan="5" colspan="1">Canada</td><td valign="top" align="left" rowspan="5" colspan="1">RCT, two arms</td><td valign="top" align="left" rowspan="5" colspan="1">Diagnosed in the 
past 4&#x02005;months</td><td valign="top" align="left" rowspan="5" colspan="1">RP, RT, ADT, watchful 
waiting or active 
surveillance</td><td valign="top" align="center" rowspan="5" colspan="1">23</td><td valign="top" align="center" rowspan="5" colspan="1">19</td><td valign="top" align="center" rowspan="5" colspan="1">64.3&#x02009;&#x000b1;&#x02009;7.7</td><td valign="top" align="center" rowspan="5" colspan="1">63.1&#x02009;&#x000b1;&#x02009;5.6</td><td valign="top" align="left" rowspan="1" colspan="1">Form: telephone</td><td valign="top" align="left" rowspan="5" colspan="1">Minimal ethical 
care (MEC)</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="5" colspan="1">Anxiety (HADS-A), depression (HADS-D), self-efficacy, quality of life, relationship satisfaction, dyadic coping (DCI), Illness appraisal, individual coping (Brief COPE)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: coping together (CT), i.e., self-directed coping skill intervention for couples facing cancer</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: fortnightly</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: 2&#x02005;months</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: clinicians</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">Lange et al. (<xref rid="B44" ref-type="bibr">44</xref>)</td><td valign="top" align="left" rowspan="5" colspan="1">Germany</td><td valign="top" align="left" rowspan="5" colspan="1">RCT, 2 arms</td><td valign="top" align="left" rowspan="5" colspan="1">&#x02014;</td><td valign="top" align="left" rowspan="5" colspan="1">Prostatectomy</td><td valign="top" align="center" rowspan="5" colspan="1">18</td><td valign="top" align="center" rowspan="5" colspan="1">26</td><td valign="top" align="center" rowspan="5" colspan="1">60.53&#x02009;&#x000b1;&#x02009;6.70</td><td valign="top" align="center" rowspan="5" colspan="1">62.77&#x02009;&#x000b1;&#x02009;6.10</td><td valign="top" align="left" rowspan="1" colspan="1">Form: telephone</td><td valign="top" align="left" rowspan="5" colspan="1">German S3 guideline 
for prostate 
cancer patients</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="5" colspan="1">Distress, anxiety, depression, anger, need for help, QOL, fear of progression (FoP) and coping with cancer</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: five group sessions in three different chat groups</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: weekly</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: each session lasted 60&#x02013;90&#x02005;min</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: psychologist</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">Galv&#x000e3;o et al. (<xref rid="B20" ref-type="bibr">20</xref>)</td><td valign="top" align="left" rowspan="5" colspan="1">Australia</td><td valign="top" align="left" rowspan="5" colspan="1">RCT, two arms</td><td valign="top" align="left" rowspan="5" colspan="1">Localized prostate 
cancer</td><td valign="top" align="left" rowspan="5" colspan="1">Have undergone 
or are currently 
undergoing 
PC treatment</td><td valign="top" align="center" rowspan="5" colspan="1">232</td><td valign="top" align="center" rowspan="5" colspan="1">231</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Form: telephone, web</td><td valign="top" align="left" rowspan="5" colspan="1">Usual care</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="5" colspan="1">Health-related QOL, disease-specific QOL, EPIC</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: peer-led intervention, self-management materials, and monthly telephone-based group peer support</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: monthly</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: 6&#x02005;months</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: peer, PC nurse counselor</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">McCaughan et al. (<xref rid="B46" ref-type="bibr">46</xref>)</td><td valign="top" align="left" rowspan="5" colspan="1">UK</td><td valign="top" align="left" rowspan="5" colspan="1">RCT, two arms</td><td valign="top" align="left" rowspan="5" colspan="1">Localized prostate 
cancer</td><td valign="top" align="left" rowspan="5" colspan="1">Post-surgical or 
post-radiotherapy 
treatment with or 
without hormone 
treatment</td><td valign="top" align="center" rowspan="5" colspan="1">26</td><td valign="top" align="center" rowspan="5" colspan="1">8</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Form: telephone</td><td valign="top" align="left" rowspan="5" colspan="1">Usual care</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="5" colspan="1">Self-efficacy; quality of life, symptom distress, communication, uncertainty and illness benefits</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: five intervention sessions</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: &#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: 9&#x02005;weeks</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: facilitator-led</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">Saengryeol et al. (<xref rid="B45" ref-type="bibr">45</xref>)</td><td valign="top" align="left" rowspan="5" colspan="1">Korea</td><td valign="top" align="left" rowspan="5" colspan="1">RCT, two arms</td><td valign="top" align="left" rowspan="5" colspan="1">Advanced PC</td><td valign="top" align="left" rowspan="5" colspan="1">ADT</td><td valign="top" align="center" rowspan="5" colspan="1">11</td><td valign="top" align="center" rowspan="5" colspan="1">10</td><td valign="top" align="center" rowspan="5" colspan="1">66.0 (61.0&#x02013;71.0)</td><td valign="top" align="center" rowspan="5" colspan="1">67.0 (59.5&#x02013;73.0)</td><td valign="top" align="left" rowspan="1" colspan="1">Form: motivational text messages</td><td valign="top" align="left" rowspan="5" colspan="1">Usual care</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="5" colspan="1">QOL, life satisfaction, anxiety and depression</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: structured lifestyle intervention</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: 2 supervision visits (week 4 and week 8) and one main tenance visit (week 12)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: 3&#x02013;8&#x02005;weeks</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: &#x02014;</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">Park et al. (<xref rid="B47" ref-type="bibr">47</xref>)</td><td valign="top" align="left" rowspan="5" colspan="1">Korea</td><td valign="top" align="left" rowspan="5" colspan="1">RCT, two arms</td><td valign="top" align="left" rowspan="5" colspan="1">&#x02014;</td><td valign="top" align="left" rowspan="5" colspan="1">ADT</td><td valign="top" align="center" rowspan="5" colspan="1">86</td><td valign="top" align="center" rowspan="5" colspan="1">86</td><td valign="top" align="center" rowspan="5" colspan="1">66.3, 65.0 (&#x000b1;6.8)</td><td valign="top" align="center" rowspan="5" colspan="1">66.5, 66.0 (&#x000b1;8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">Form: Android-based smartphone, a smartphone application, a web-based platform, and a smartband (Neofit band, KT, Korea)</td><td valign="top" align="left" rowspan="5" colspan="1">Usual care</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="5" colspan="1">Vital sign measurements, physical measurements, cardiorespiratory endurance, physical strength, self-reported physical activity, QOL</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: The Smart After-Care (SAC) service</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: weekly</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: 12&#x02005;weeks</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: physicians, clinical nutritionists, and exercise therapists</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">Benzo et al. (<xref rid="B19" ref-type="bibr">19</xref>)</td><td valign="top" align="left" rowspan="5" colspan="1">USA</td><td valign="top" align="left" rowspan="5" colspan="1">RCT, two arms</td><td valign="top" align="left" rowspan="5" colspan="1">Stage-III or IV 
prostate cancer</td><td valign="top" align="left" rowspan="5" colspan="1">ADT</td><td valign="top" align="center" rowspan="5" colspan="1">95</td><td valign="top" align="center" rowspan="5" colspan="1">97</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="center" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Form: web</td><td valign="top" align="left" rowspan="5" colspan="1">Health promotion 
(HP)</td><td valign="top" align="left" rowspan="5" colspan="1">NA</td><td valign="top" align="left" rowspan="5" colspan="1">Five domains of symptom-related quality of life</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: cognitive-behavioral stress management (CBSM)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: weekly</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: 10&#x02005;weeks</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: clinical psychologists</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">Lambert et al. (<xref rid="B21" ref-type="bibr">21</xref>)</td><td valign="top" align="left" rowspan="5" colspan="1">Canada</td><td valign="top" align="left" rowspan="5" colspan="1">RCT, two arms</td><td valign="top" align="left" rowspan="5" colspan="1">Prostate cancer 
(local or 
metastasized)</td><td valign="top" align="left" rowspan="5" colspan="1">Surgery, chemotherapy, 
radiation therapy, 
hormone therapy, 
and/or brachytherapy</td><td valign="top" align="center" rowspan="5" colspan="1">26</td><td valign="top" align="center" rowspan="5" colspan="1">23</td><td valign="top" align="center" rowspan="5" colspan="1">&#x02264;60: 6 (23.1), 
&#x02265;61: 20 (76.9)</td><td valign="top" align="center" rowspan="5" colspan="1">&#x02264;60: 6 (26.1), 
&#x02265;61: 17 (73.9)</td><td valign="top" align="left" rowspan="1" colspan="1">Forms: web</td><td valign="top" align="left" rowspan="5" colspan="1">Usual care</td><td valign="top" align="left" rowspan="5" colspan="1">Stress and coping 
framework, 
framework of dyadic 
coping, self-efficacy 
theory</td><td valign="top" align="left" rowspan="5" colspan="1">Anxiety, QOL, depression, self-management skills, physical activity, self-efficacy, appraisal</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Content: TEMPO&#x02014;the first dyadic, tailored, web-based, psychosocial and physical activity self-Management PrOgram feedback</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency: &#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time: 10&#x02005;weeks</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervenor: RAs</td></tr></tbody></table><table-wrap-foot><fn><p>RP, radical prostatectomy; RT, radiation therapy, ADT, Androgen deprivation therapy, CD, Compact disc.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><label>3.2</label><title>Risk of bias assessment</title><p>The Cochrane Collaboration RoB tool was used to assess the RoB of the included studies. The domains for assessment included selection bias, including sequence generation and allocation sequence concealment; performance or detection bias via blinding of participants, personnel, and outcome assessors; attrition bias via incomplete outcome data; and reporting bias via selective outcome reporting. The criteria for low, unclear, and high RoB within and across the studies followed the Cochrane Handbook for Systematic Reviews of Interventions. RoB was independently assessed by authors HSC (five articles), HH (three articles), and HHL (three articles). YML reviewed all RoB assessments to confirm accuracy. In addition, data integrity and selective reporting were both assessed as low risk. The results are presented in <xref rid="F2" ref-type="fig">Figure&#x000a0;2</xref>.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Risk of bias summary.</p></caption><graphic xlink:href="fdgth-07-1584764-g002" position="float"/></fig></sec><sec id="s3c"><label>3.3</label><title>Meta-analysis of primary outcomes</title><p>Six RCTs (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B45" ref-type="bibr">45</xref>) (<italic>n</italic>&#x02009;=&#x02009;687 participants) reported the short-term effect of the intervention on anxiety, and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group [SMD&#x02009;=&#x02009;&#x02212;0.07, 95% confidence interval (CI)&#x02009;=&#x02009;&#x02212;0.43 to 0.29, <italic>P</italic>&#x02009;=&#x02009;0.70, I<sup>2</sup>&#x02009;=&#x02009;63.30%] (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>). The long-term effects of the interventions on anxiety were measured in two studies (<italic>n</italic>&#x02009;=&#x02009;419 participants) (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B42" ref-type="bibr">42</xref>), and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;&#x02212;0.11, 95% CI&#x02009;=&#x02009;&#x02212;0.30 to 0.08, <italic>P</italic>&#x02009;=&#x02009;0.26, I<sup>2</sup>&#x02009;=&#x02009;0.00%) (<xref rid="T3" ref-type="table">Table&#x000a0;3</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>The short-term effect of mHealth interventions on anxiety, depression, self-efficacy, psychological distress, urinary function, and bowel function outcomes from randomized controlled trials.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Outcome</th><th valign="top" align="center" rowspan="2" colspan="1">Studies</th><th valign="top" align="center" colspan="2" rowspan="1">No. of 
participants</th><th valign="top" align="center" rowspan="1" colspan="1">Heterogeneity 
test I<sup>2</sup>(%)</th><th valign="top" align="center" colspan="4" rowspan="1">Effect size</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Trial</th><th valign="top" align="center" rowspan="1" colspan="1">Control</th><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">SMD</th><th valign="top" align="center" colspan="2" rowspan="1">95% CI</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Anxiety</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">283</td><td valign="top" align="center" rowspan="1" colspan="1">306</td><td valign="top" align="center" rowspan="1" colspan="1">63.30</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.07</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.43</td><td valign="top" align="center" rowspan="1" colspan="1">0.29</td><td valign="top" align="center" rowspan="1" colspan="1">0.70</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Depression</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">283</td><td valign="top" align="center" rowspan="1" colspan="1">306</td><td valign="top" align="center" rowspan="1" colspan="1">54.23</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.08</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.40</td><td valign="top" align="center" rowspan="1" colspan="1">0.24</td><td valign="top" align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Self-efficacy</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">31</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.02</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.84</td><td valign="top" align="center" rowspan="1" colspan="1">0.44</td><td valign="top" align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Psychological distress</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">64</td><td valign="top" align="center" rowspan="1" colspan="1">45.39</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.01</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.52</td><td valign="top" align="center" rowspan="1" colspan="1">0.50</td><td valign="top" align="center" rowspan="1" colspan="1">0.96</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urinary function</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">259</td><td valign="top" align="center" rowspan="1" colspan="1">280</td><td valign="top" align="center" rowspan="1" colspan="1">54.45</td><td valign="top" align="center" rowspan="1" colspan="1">0.22</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.05</td><td valign="top" align="center" rowspan="1" colspan="1">0.05</td><td valign="top" align="center" rowspan="1" colspan="1">0.12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bowel function</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">259</td><td valign="top" align="center" rowspan="1" colspan="1">280</td><td valign="top" align="center" rowspan="1" colspan="1">71.41</td><td valign="top" align="center" rowspan="1" colspan="1">0.21</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.14</td><td valign="top" align="center" rowspan="1" colspan="1">0.57</td><td valign="top" align="center" rowspan="1" colspan="1">0.24</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p>The short-term effect was measured after the end of the intervention, and the measured outcome indicators were followed up for &#x02264;3&#x02005;months.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>The long-term effect of mHealth interventions on anxiety, depression, urinary function, bowel function, hormonal function and sexual function outcomes from randomized controlled trials.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Outcome</th><th valign="top" align="center" rowspan="2" colspan="1">Studies</th><th valign="top" align="center" colspan="2" rowspan="1">No. of 
participants</th><th valign="top" align="center" rowspan="1" colspan="1">Heterogeneity 
test I2(%)</th><th valign="top" align="center" colspan="4" rowspan="1">Effect size</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Trial</th><th valign="top" align="center" rowspan="1" colspan="1">Control</th><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">SMD</th><th valign="top" align="center" colspan="2" rowspan="1">95% CI</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Anxiety</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">208</td><td valign="top" align="center" rowspan="1" colspan="1">211</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.11</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.30</td><td valign="top" align="center" rowspan="1" colspan="1">0.08</td><td valign="top" align="center" rowspan="1" colspan="1">0.26</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Depression</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">221</td><td valign="top" align="center" rowspan="1" colspan="1">225</td><td valign="top" align="center" rowspan="1" colspan="1">26.09</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.18</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.49</td><td valign="top" align="center" rowspan="1" colspan="1">0.13</td><td valign="top" align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urinary function</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">255</td><td valign="top" align="center" rowspan="1" colspan="1">274</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">0.06</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.11</td><td valign="top" align="center" rowspan="1" colspan="1">0.23</td><td valign="top" align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bowel function</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">228</td><td valign="top" align="center" rowspan="1" colspan="1">245</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">0.19</td><td valign="top" align="center" rowspan="1" colspan="1">0.01</td><td valign="top" align="center" rowspan="1" colspan="1">0.37</td><td valign="top" align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hormonal function</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">245</td><td valign="top" align="center" rowspan="1" colspan="1">267</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">0.11</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.06</td><td valign="top" align="center" rowspan="1" colspan="1">0.28</td><td valign="top" align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sexual function</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">389</td><td valign="top" align="center" rowspan="1" colspan="1">348</td><td valign="top" align="center" rowspan="1" colspan="1">93.82</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.05</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.67</td><td valign="top" align="center" rowspan="1" colspan="1">0.56</td><td valign="top" align="center" rowspan="1" colspan="1">0.86</td></tr></tbody></table><table-wrap-foot><fn id="table-fn2"><p>The long-term effect was measured after the end of the intervention, and the measured outcome indicators were followed up for &#x0003e;3&#x02005;months.</p></fn></table-wrap-foot></table-wrap><p>Six RCTs (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B45" ref-type="bibr">45</xref>) (<italic>n</italic>&#x02009;=&#x02009;589 participants) reported the short-term effect of the intervention on depression, and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;&#x02212;0.08, 95% CI&#x02009;=&#x02009;&#x02212;0.40 to 0.24, <italic>P</italic>&#x02009;=&#x02009;0.63, I<sup>2</sup>&#x02009;=&#x02009;54.23%) (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>). The long-term effects of the interventions on depression were measured in three studies (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B42" ref-type="bibr">42</xref>) (<italic>n</italic>&#x02009;=&#x02009;446 participants), and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;&#x02212;0.18, 95% CI&#x02009;=&#x02009;&#x02212;0.49 to 0.13, <italic>P</italic>&#x02009;=&#x02009;0.25, I<sup>2</sup>&#x02009;=&#x02009;26.09%) (<xref rid="T3" ref-type="table">Table&#x000a0;3</xref>).</p><p>Two RCTs (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B46" ref-type="bibr">46</xref>) (<italic>n</italic>&#x02009;=&#x02009;46 participants) reported the short-term effect of the interventions on self-efficacy, and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;&#x02212;0.02, 95% CI&#x02009;=&#x02009;&#x02212;0.84 to 0.44, <italic>P</italic>&#x02009;=&#x02009;0.54, I<sup>2</sup>&#x02009;=&#x02009;0.00%) (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>).</p><p>Four RCTs (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B46" ref-type="bibr">46</xref>) (<italic>n</italic>&#x02009;=&#x02009;134 participants) reported the short-term effect of the interventions on psychological distress, and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;&#x02212;0.01, 95% CI&#x02009;=&#x02009;&#x02212;0.52 to 0.50, <italic>P</italic>&#x02009;=&#x02009;0.96, I<sup>2</sup>&#x02009;=&#x02009;45.39%) (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>).</p><p>Two RCTs (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B47" ref-type="bibr">47</xref>) (<italic>n</italic>&#x02009;=&#x02009;539 participants) reported the short-term effect of the interventions on urinary function, and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;0.22, 95% CI&#x02009;=&#x02009;&#x02212;0.05 to 0.50, <italic>P</italic>&#x02009;=&#x02009;0.12, I<sup>2</sup>&#x02009;=&#x02009;54.45%) (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>). The long-term effects of the interventions on urinary function were measured in three studies (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B41" ref-type="bibr">41</xref>) (<italic>n</italic>&#x02009;=&#x02009;529 participants), and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;0.06, 95% CI&#x02009;=&#x02009;&#x02212;0.11 to 0.23, <italic>P</italic>&#x02009;=&#x02009;0.51, I<sup>2</sup>&#x02009;=&#x02009;0.00%) (<xref rid="T3" ref-type="table">Table&#x000a0;3</xref>).</p><p>Two RCTs (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B47" ref-type="bibr">47</xref>) (<italic>n</italic>&#x02009;=&#x02009;539 participants) reported the short-term effect of the interventions on bowel function, and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;0.21, 95% CI&#x02009;=&#x02009;&#x02212;0.14 to 0.57, <italic>P</italic>&#x02009;=&#x02009;0.24, I<sup>2</sup>&#x02009;=&#x02009;71.41%) (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>). The long-term effects of the interventions on bowel function were measured in three studies (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B41" ref-type="bibr">41</xref>) (<italic>n</italic>&#x02009;=&#x02009;473 participants), and the meta-analysis demonstrated a significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;0.19, 95% CI&#x02009;=&#x02009;0.01&#x02013;0.37, <italic>P</italic>&#x02009;=&#x02009;0.04, I<sup>2</sup>&#x02009;=&#x02009;0.00%) (<xref rid="F3" ref-type="fig">Figure&#x000a0;3</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Forest plot of the long-term effect of mHealth interventions on bowel function.</p></caption><graphic xlink:href="fdgth-07-1584764-g003" position="float"/></fig><p>The long-term effects of the interventions on hormonal function were measured in two studies (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>) (<italic>n</italic>&#x02009;=&#x02009;512 participants), and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;0.11, 95% CI&#x02009;=&#x02009;&#x02212;0.06 to 0.28, <italic>P</italic>&#x02009;=&#x02009;0.21, I<sup>2</sup>&#x02009;=&#x02009;0.00%) (<xref rid="T3" ref-type="table">Table&#x000a0;3</xref>).</p><p>The long-term effects of the interventions on sexual function were measured in four studies (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B41" ref-type="bibr">41</xref>) (<italic>n</italic>&#x02009;=&#x02009;737 participants), and the meta-analysis demonstrated no significant difference between the mHealth intervention group and the control group (SMD&#x02009;=&#x02009;&#x02212;0.05, 95% CI&#x02009;=&#x02009;&#x02212;0.67to 0.56, <italic>P</italic>&#x02009;=&#x02009;0.86, I<sup>2</sup>&#x02009;=&#x02009;93.82%) (<xref rid="T3" ref-type="table">Table&#x000a0;3</xref>).</p></sec><sec id="s3d"><label>3.4</label><title>Meta-analysis of secondary outcomes</title><p>As for the secondary outcomes (<xref rid="T4" ref-type="table">Table&#x000a0;4</xref>), the meta-analysis demonstrated no significant differences in the short-term effects of the interventions on quality of life, mental health, and physical health. Three health-related QOL (HRQOL) measures, validated in patients with prostate cancer, were used: the physical and mental scales of the Assessment of Quality of Life-8 Dimensions (AQoL-8D) (<xref rid="B43" ref-type="bibr">43</xref>), the 8-item Short Form Health Survey (SF-8) (<xref rid="B44" ref-type="bibr">44</xref>), and the 12-item Short Form Health Survey (SF-12) (<xref rid="B21" ref-type="bibr">21</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Meta-analysis of secondary outcomes.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Outcome</th><th valign="top" align="center" rowspan="2" colspan="1">Studies</th><th valign="top" align="center" colspan="2" rowspan="1">No. of 
participants</th><th valign="top" align="center" rowspan="1" colspan="1">Heterogeneity 
test I<sup>2</sup>(%)</th><th valign="top" align="center" colspan="4" rowspan="1">Effect size</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Trial</th><th valign="top" align="center" rowspan="1" colspan="1">Control</th><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">SMD</th><th valign="top" align="center" colspan="2" rowspan="1">95% CI</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Quality of life</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">207</td><td valign="top" align="center" rowspan="1" colspan="1">219</td><td valign="top" align="center" rowspan="1" colspan="1">43.58</td><td valign="top" align="center" rowspan="1" colspan="1">0.10</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.44</td><td valign="top" align="center" rowspan="1" colspan="1">0.64</td><td valign="top" align="center" rowspan="1" colspan="1">0.71</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mental health</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">58</td><td valign="top" align="center" rowspan="1" colspan="1">62</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.11</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.47</td><td valign="top" align="center" rowspan="1" colspan="1">0.25</td><td valign="top" align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Physical health</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">58</td><td valign="top" align="center" rowspan="1" colspan="1">62</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.13</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.49</td><td valign="top" align="center" rowspan="1" colspan="1">0.23</td><td valign="top" align="center" rowspan="1" colspan="1">0.48</td></tr></tbody></table><table-wrap-foot><fn id="table-fn3"><p>The short-term effect of mHealth interventions on quality of life, mental health, and physical health outcomes from randomized controlled trials.</p></fn></table-wrap-foot></table-wrap><p>Three RCTs (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B41" ref-type="bibr">41</xref>) reported that the mHealth interventions were delivered by professional technical personnel, and one RCT (<xref rid="B22" ref-type="bibr">22</xref>) reported that the mHealth intervention was delivered by peer support volunteers. In the sensitivity analyses (<xref rid="T5" ref-type="table">Table&#x000a0;5</xref>), after removing the RCT of Chambers et al. (<xref rid="B22" ref-type="bibr">22</xref>), the sexual function differences became statistically significant. However, since only three studies were included, further research is needed to explore these findings. Subgroup analysis was conducted on data of tumor stage and intervention type (<xref rid="F4" ref-type="fig">Figure 4</xref>). Relevant hypothesis tests indicated no significant differences.</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Sensitivity analysis of intervention heterogeneity.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">All studies</th><th valign="top" align="center" rowspan="1" colspan="1">Omitted Chambers (<xref rid="B22" ref-type="bibr">22</xref>)</th><th valign="top" align="center" rowspan="1" colspan="1">Omitted Saengryeol (<xref rid="B45" ref-type="bibr">45</xref>)</th><th valign="top" align="center" rowspan="1" colspan="1">Omitted Lambert (<xref rid="B21" ref-type="bibr">21</xref>)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Sexual function</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02212;0.05 (&#x02212;0.67 to 0.56)</td><td valign="top" align="center" rowspan="2" colspan="1">0.24 (0.06 to 0.43)</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02014;</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SMD (95% CI)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Depression</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02212;0.08 (&#x02212;0.40 to 0.24)</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02014;</td><td valign="top" align="center" rowspan="2" colspan="1">0.11 (&#x02212;0.31 to 0.10)</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02212;0.17 (&#x02212;0.49 to 0.15)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SMD (95% CI)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Anxiety</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02212;0.07 (&#x02212;0.43 to 0.28)</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02014;</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02212;0.09 (&#x02212;0.26 to 0.07)</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02014;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SMD (95% CI)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Quality of life</td><td valign="top" align="center" rowspan="2" colspan="1">0.10 (&#x02212;0.44 to 0.64)</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02014;</td><td valign="top" align="center" rowspan="2" colspan="1">0.02 (&#x02212;0.17 to 0.22)</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02212;0.01 (&#x02212;0.47 to 0.44)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SMD (95% CI)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Psychological distress</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02212;0.01 (&#x02212;0.52 to 0.50)</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02014;</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02014;</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02212;0.05 (&#x02212;0.81 to 0.70)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SMD (95% CI)</td></tr></tbody></table><table-wrap-foot><fn id="table-fn4"><p>SMD, standardized mean difference. &#x02014; indicates that the trial was not included in this outcome and a sensitivity analysis could not be performed.</p></fn><fn id="table-fn5"><p>Studies with peer support volunteers or interventions that relied entirely on mHealth were excluded.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F4"><label>Figure 4</label><caption><p>Subgroup analysis.</p></caption><graphic xlink:href="fdgth-07-1584764-g004" position="float"/></fig></sec><sec id="s3e"><label>3.5</label><title>Publication bias</title><p>Fewer than 10 articles were included for each outcome, and thus, an assessment of publication bias could not be conducted.</p></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>This meta-analysis included 11 RCTs involving 1,368 participants and provided evidence that mHealth interventions significantly improve long-term bowel function outcomes. Moreover, in the sensitivity analyses, the sexual function differences became statistically significant. However, mHealth interventions did not significantly reduce symptom distress (anxiety, depression, self-efficacy, psychological distress, urinary function, bowel function, and hormonal function outcomes) or improve quality of life.</p><p>Our findings are consistent with previous systematic literature reviews (<xref rid="B48" ref-type="bibr">48</xref>), which concluded that technology-based interventions (TBIs) cannot improve health outcomes (anxiety, depression, and HRQOL) among patients with prostate cancer. However, the present meta-analysis included more patient outcomes, such as self-efficacy, psychological distress, urinary function, bowel function, and hormonal function, to further explore the short-term and long-term effects of mHealth interventions.</p><p>The mHealth interventions did not improve anxiety, depression, or psychological distress symptoms. This result may be due to a floor effect, whereby participants' baseline anxiety, depression, and psychological distress symptom scores were within the healthy range. The incidence of anxiety, depression, and psychological distress among patients with prostate cancer ranges from 15% to 22% (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>), 14.7% to 65.9% (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>), and 21% to 28% (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>), respectively. The studies in this review did not recruit patients with anxiety or depression. In primary care, some evidence suggests that mHealth interventions can decrease anxiety, depression, and psychological distress symptoms, and there is growing evidence of their benefits in cancer care (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B55" ref-type="bibr">55</xref>). However, more research is needed to evaluate their effectiveness in patients with prostate cancer experiencing anxiety, depression, and psychological distress.</p><p>The present study did not find that mHealth interventions can significantly improve patients' urinary, bowel, and hormonal function outcomes, probably due to the small number of included studies (only two or three RCTs) or the fact that the included population did not comprise patients with advanced prostate cancer. Moreover, the content and frequency of mHealth interventions may not have been standardized across studies, as latest RCTs indicate that targeting a web-based intervention to recipients most likely to benefit patients with elevated levels of symptom burden and can improve urinary irritation, bowel function, hormonal function, and depression symptoms in men with PC (<xref rid="B19" ref-type="bibr">19</xref>). For the symptoms mentioned above, data from the studies incorporated were inconsistent, making conclusions regarding their management through mHealth interventions difficult to draw. However, the long-term effects of mHealth interventions on bowel function had a significant positive impact. Several hypotheses could explain why we observed improvements over time in these conditions. First, we hypothesize that the &#x0201c;attention&#x0201d; provided to participants (60&#x02013;90&#x02005;min/session in the intervention group and 0&#x02013;60&#x02005;min/session in the control group) by the study staff could have played a role in the improvement of symptoms over time in these conditions. Second, participation bias (e.g., participants' desire to reduce their stress) may also partially explain why individuals in these conditions improved their outcomes. Finally, we also hypothesize that improvement in bowel function across conditions could be attributed to the overlapping content presented (e.g., education component, attention, and social support). This is consistent with previous work that showed mHealth interventions as a possible method for reducing the severity of participants' irritable bowel syndrome symptoms (<xref rid="B56" ref-type="bibr">56</xref>), and a review that concluded that mHealth interventions were associated with significant reductions in bowel symptoms and improvement in quality of life that tended to continue up to 12&#x02005;months of follow-up (<xref rid="B57" ref-type="bibr">57</xref>). More research is needed to elucidate and disentangle the effects of mHealth interventions on symptom-related quality of life among prostate cancer survivors.</p><p>Quality of life is related to physical health, psychological conditions, social relationships, and environment (<xref rid="B58" ref-type="bibr">58</xref>). mHealth interventions likely cannot improve quality of life and self-efficacy because mHealth interventions fail to improve the symptom-related distress and psychological distress of patients with prostate cancer. This result may be due to the quality of life and the self-efficacy of these men already being at normative levels at baseline, and they may not have needed an intervention. However, a recent review found that mHealth interventions are promising for improving the QOL of patients with cancer, and the strongest evidence exists for physical activity interventions, followed by mindfulness and cognitive behavioral therapy (<xref rid="B59" ref-type="bibr">59</xref>). This meta-analysis only included two articles on physical activity interventions and one article on cognitive behavioral therapy interventions, thus, robust conclusions cannot be drawn from the available evidence.</p><p>The latest studies show that cancer survivors benefit variably from mHealth tools (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B60" ref-type="bibr">60</xref>). To maximize the effects of such tools, future research should consider the following aspects. First, positive associations have primarily been demonstrated between mHealth/digital literacy levels and the utilization of the Internet as part of information-seeking related to healthcare and prostate cancer; however, PC survivors' mHealth literacy levels were likely to be at a novice level. Therefore, it is necessary for us to reliably measure mHealth literacy, improve our ability to identify low-literacy target groups, and develop and test interventions to effect change (<xref rid="B61" ref-type="bibr">61</xref>). Second, another research study found that mHealth intervention personalization improves engagement and efficacy (<xref rid="B62" ref-type="bibr">62</xref>). Future studies should consider using the technology acceptance model to codesign mHealth interventions with end-users and analyze end-user personalization regarding engagement and health outcomes (<xref rid="B15" ref-type="bibr">15</xref>). Third, a retrospective study demonstrated that utilizing mobile Internet management for the ongoing care of patients who have undergone radical prostatectomy yields significant benefits because the invasive nature of radical prostatectomy often induces psychological stress (<xref rid="B63" ref-type="bibr">63</xref>). Future research could start with the treatment methods adopted by patients and analyze whether different treatment approaches have an impact on the physical and mental outcomes of patients. Fourth, future mobile health interventions should be based on patients' unique needs and preferences, considering critical factors for implementing mHealth interventions, including perceived utility, ease of use, and resolving technical barriers such as privacy, cost, and security, as well as the remote monitoring of patients' progress. Importantly, intervention measures designed jointly with end-users can enhance participation.</p><p>The present meta-analysis had several limitations. First, due to the limited number of included articles, we could not fully evaluate publication bias, which resulted in low statistical efficiency. Second, most interventions were delivered over a relatively short period, typically ranging from 6 to 10&#x02005;weeks; most frequently, the interventions were provided weekly. However, the lack of data prevented the comparison of mHealth interventions by length or frequency of the intervention. In the same way, evidence was insufficient to enable comparison by neoplasm staging and perform subgroup analyses, which would have been useful because an RCT suggests that different forms of interventions may be more or less effective according to disease stage (<xref rid="B64" ref-type="bibr">64</xref>). Finally, different instruments were used to assess patient outcomes, which made a comparison of the results difficult.</p></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusions</title><p>The results of this systematic review and meta-analysis indicate that patients with prostate cancer benefit less from mHealth interventions both mentally (anxiety, depression, self-efficacy, psychological distress, and quality of life) and physically (urinary function and hormonal function). However, mHealth interventions significantly improved long-term bowel function outcomes. Further, we need studies with sufficient statistical power and length of follow-up to generate much-needed definitive evidence concerning the efficacy of mHealth interventions for the management of symptoms in patients with prostate cancer.</p></sec></body><back><fn-group><title>Abbreviations</title><fn fn-type="abbr" id="ab001"><p>PRISMA, Preferred Reporting Items for Systematic review and Meta-Analyses guidelines; RCTs, randomized controlled trials; PC, prostate cancer; QOL, quality of life.</p></fn></fn-group><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="s11" ref-type="sec">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>HSC: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. HH: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Writing &#x02013; original draft. HHL: Data curation, Formal analysis, Investigation, Methodology, Software, Writing &#x02013; original draft. YZ: Data curation, Investigation, Methodology, Software, Writing &#x02013; original draft. NL: Investigation, Software, Writing &#x02013; original draft. YML: Conceptualization, Project administration, Supervision, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s11"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fdgth.2025.1584764/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fdgth.2025.1584764/full#supplementary-material</ext-link></p><supplementary-material id="SD1" position="float" content-type="local-data"><media xlink:href="Datasheet1.pdf" id="d100e1899" position="anchor"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brausi</surname><given-names>M</given-names></name><name><surname>Hoskin</surname><given-names>P</given-names></name><name><surname>Andritsch</surname><given-names>E</given-names></name><name><surname>Banks</surname><given-names>I</given-names></name><name><surname>Beishon</surname><given-names>M</given-names></name><name><surname>Boyle</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>ECCO essential requirements for quality cancer care: prostate cancer</article-title>. <source>Crit Rev Oncol Hematol</source>. (<year>2020</year>) <volume>148</volume>:<fpage>102861</fpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2019.102861</pub-id><pub-id pub-id-type="pmid">32151466</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. (<year>2021</year>) <volume>71</volume>(<issue>3</issue>):<fpage>209</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mundle</surname><given-names>R</given-names></name><name><surname>Afenya</surname><given-names>E</given-names></name><name><surname>Agarwal</surname><given-names>N</given-names></name></person-group>. <article-title>The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature</article-title>. <source>Prostate Cancer Prostatic Dis</source>. (<year>2021</year>) <volume>24</volume>(<issue>3</issue>):<fpage>674</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1038/s41391-021-00342-3</pub-id><pub-id pub-id-type="pmid">33750905</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spratt</surname><given-names>DE</given-names></name><name><surname>Shore</surname><given-names>N</given-names></name><name><surname>Sartor</surname><given-names>O</given-names></name><name><surname>Rathkopf</surname><given-names>D</given-names></name><name><surname>Olivier</surname><given-names>K</given-names></name></person-group>. <article-title>Treating the patient and not just the cancer: therapeutic burden in prostate cancer</article-title>. <source>Prostate Cancer Prostatic Dis</source>. (<year>2021</year>) <volume>24</volume>(<issue>3</issue>):<fpage>647</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1038/s41391-021-00328-1</pub-id><pub-id pub-id-type="pmid">33603236</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazlauskas</surname><given-names>E</given-names></name><name><surname>Patasius</surname><given-names>A</given-names></name><name><surname>Kvedaraite</surname><given-names>M</given-names></name><name><surname>Nomeikaite</surname><given-names>A</given-names></name><name><surname>Rudyte</surname><given-names>M</given-names></name><name><surname>Smailyte</surname><given-names>G</given-names></name></person-group>. <article-title>Icd-11 adjustment disorder following diagnostic procedures of prostate cancer: a 12-month follow-up study</article-title>. <source>J Psychosom Res</source>. (<year>2023</year>) <volume>168</volume>:<fpage>111214</fpage>. <pub-id pub-id-type="doi">10.1016/j.jpsychores.2023.111214</pub-id><pub-id pub-id-type="pmid">36905705</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Awamlh</surname><given-names>BA</given-names></name><name><surname>Wallis</surname><given-names>CJD</given-names></name><name><surname>Penson</surname><given-names>DF</given-names></name><name><surname>Huang</surname><given-names>LC</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Conwill</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Functional outcomes after localized prostate cancer treatment</article-title>. <source>Jama</source>. (<year>2024</year>) <volume>331</volume>(<issue>4</issue>):<fpage>302</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2023.26491</pub-id><pub-id pub-id-type="pmid">38261043</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>CJD</given-names></name><name><surname>Glaser</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>JC</given-names></name><name><surname>Huland</surname><given-names>H</given-names></name><name><surname>Lawrentschuk</surname><given-names>N</given-names></name><name><surname>Moon</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Survival and complications following surgery and radiation for localized prostate cancer: an international collaborative review</article-title>. <source>Eur Urol</source>. (<year>2018</year>) <volume>73</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2017.05.055</pub-id><pub-id pub-id-type="pmid">28610779</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>RK</given-names></name><name><surname>Cheung</surname><given-names>P</given-names></name><name><surname>Herschorn</surname><given-names>S</given-names></name><name><surname>Saskin</surname><given-names>R</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Klotz</surname><given-names>LH</given-names></name><etal/></person-group>
<article-title>Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study</article-title>. <source>Lancet Oncol</source>. (<year>2014</year>) <volume>15</volume>(<issue>2</issue>):<fpage>223</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(13)70606-5</pub-id><pub-id pub-id-type="pmid">24440474</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ficarra</surname><given-names>V</given-names></name><name><surname>Novara</surname><given-names>G</given-names></name><name><surname>Rosen</surname><given-names>RC</given-names></name><name><surname>Artibani</surname><given-names>W</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Costello</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy</article-title>. <source>Eur Urol</source>. (<year>2012</year>) <volume>62</volume>(<issue>3</issue>):<fpage>405</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2012.05.045</pub-id><pub-id pub-id-type="pmid">22749852</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holm</surname><given-names>M</given-names></name><name><surname>Doveson</surname><given-names>S</given-names></name><name><surname>Lindqvist</surname><given-names>O</given-names></name><name><surname>Wennman-Larsen</surname><given-names>A</given-names></name><name><surname>Fransson</surname><given-names>P</given-names></name></person-group>. <article-title>Quality of life in men with metastatic prostate cancer in their final years before death&#x02014;a retrospective analysis of prospective data</article-title>. <source>BMC Palliat Care</source>. (<year>2018</year>) <volume>17</volume>(<issue>1</issue>):<fpage>126</fpage>. <pub-id pub-id-type="doi">10.1186/s12904-018-0381-6</pub-id><pub-id pub-id-type="pmid">30509249</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noriega Esquives</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>TK</given-names></name><name><surname>Moreno</surname><given-names>PI</given-names></name><name><surname>Fox</surname><given-names>RS</given-names></name><name><surname>Yanez</surname><given-names>B</given-names></name><name><surname>Miller</surname><given-names>GE</given-names></name><etal/></person-group>
<article-title>Symptom burden profiles in men with advanced prostate cancer undergoing androgen deprivation therapy</article-title>. <source>J Behav Med</source>. (<year>2022</year>) <volume>45</volume>(<issue>3</issue>):<fpage>366</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/s10865-022-00288-4</pub-id><pub-id pub-id-type="pmid">35107655</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crump</surname><given-names>C</given-names></name><name><surname>Stattin</surname><given-names>P</given-names></name><name><surname>Brooks</surname><given-names>JD</given-names></name><name><surname>Sundquist</surname><given-names>J</given-names></name><name><surname>Bill-Axelson</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>AC</given-names></name><etal/></person-group>
<article-title>Long-term risks of depression and suicide among men with prostate cancer: a national cohort study</article-title>. <source>Eur Urol</source>. (<year>2023</year>) <volume>84</volume>(<issue>3</issue>):<fpage>263</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2023.04.026</pub-id><pub-id pub-id-type="pmid">37169640</pub-id>
</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosoni</surname><given-names>S</given-names></name><name><surname>Voruganti</surname><given-names>I</given-names></name><name><surname>Lajkosz</surname><given-names>K</given-names></name><name><surname>Mustafa</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>Patient consent preferences on sharing personal health information during the COVID-19 pandemic: &#x0201c;the more informed we are, the more likely we are to help&#x0201d;</article-title>. <source>BMC Med Ethics</source>. (<year>2022</year>) <volume>23</volume>(<issue>1</issue>):<fpage>53</fpage>. <pub-id pub-id-type="doi">10.1186/s12910-022-00790-z</pub-id><pub-id pub-id-type="pmid">35596210</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittberg</surname><given-names>R</given-names></name><name><surname>Mann</surname><given-names>A</given-names></name><name><surname>Desautels</surname><given-names>D</given-names></name><name><surname>Earle</surname><given-names>CC</given-names></name><name><surname>Navaratnam</surname><given-names>S</given-names></name><name><surname>Pitz</surname><given-names>M</given-names></name></person-group>. <article-title>Canadian cancer centre response to COVID-19 pandemic: a national and provincial response</article-title>. <source>Curr Oncol</source>. (<year>2020</year>) <volume>28</volume>(<issue>1</issue>):<fpage>233</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.3390/curroncol28010026</pub-id><pub-id pub-id-type="pmid">33704191</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singleton</surname><given-names>AC</given-names></name><name><surname>Raeside</surname><given-names>R</given-names></name><name><surname>Hyun</surname><given-names>KK</given-names></name><name><surname>Partridge</surname><given-names>SR</given-names></name><name><surname>Di Tanna</surname><given-names>GL</given-names></name><name><surname>Hafiz</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Electronic health interventions for patients with breast cancer: systematic review and meta-analyses</article-title>. <source>J Clin Oncol</source>. (<year>2022</year>) <volume>40</volume>(<issue>20</issue>):<fpage>2257</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1200/jco.21.01171</pub-id><pub-id pub-id-type="pmid">35500200</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ream</surname><given-names>E</given-names></name><name><surname>Hughes</surname><given-names>AE</given-names></name><name><surname>Cox</surname><given-names>A</given-names></name><name><surname>Skarparis</surname><given-names>K</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Pedersen</surname><given-names>VH</given-names></name><etal/></person-group>
<article-title>Telephone interventions for symptom management in adults with cancer</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2020</year>) <volume>6</volume>(<issue>6</issue>):<fpage>Cd007568</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD007568.pub2</pub-id><pub-id pub-id-type="pmid">32483832</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamnadass</surname><given-names>E</given-names></name><name><surname>Rai</surname><given-names>BP</given-names></name><name><surname>Veneziano</surname><given-names>D</given-names></name><name><surname>Tokas</surname><given-names>T</given-names></name><name><surname>Rivas</surname><given-names>JG</given-names></name><name><surname>Cacciamani</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Do prostate cancer-related mobile phone apps have a role in contemporary prostate cancer management? A systematic review by Eau young academic urologists (Yau) urotechnology group</article-title>. <source>World J Urol</source>. (<year>2020</year>) <volume>38</volume>(<issue>10</issue>):<fpage>2411</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1007/s00345-020-03197-w</pub-id><pub-id pub-id-type="pmid">32322996</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogunsanya</surname><given-names>ME</given-names></name><name><surname>Sifat</surname><given-names>M</given-names></name><name><surname>Bamidele</surname><given-names>OO</given-names></name><name><surname>Ezenwankwo</surname><given-names>EF</given-names></name><name><surname>Clifton</surname><given-names>S</given-names></name><name><surname>Ton</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Mobile health (Mhealth) interventions in prostate cancer survivorship: a scoping review</article-title>. <source>J Cancer Surviv</source>. (<year>2023</year>) <volume>17</volume>(<issue>3</issue>):<fpage>557</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1007/s11764-022-01328-3</pub-id><pub-id pub-id-type="pmid">36627464</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benzo</surname><given-names>RM</given-names></name><name><surname>Moreno</surname><given-names>PI</given-names></name><name><surname>Noriega-Esquives</surname><given-names>B</given-names></name><name><surname>Otto</surname><given-names>AK</given-names></name><name><surname>Penedo</surname><given-names>FJ</given-names></name></person-group>. <article-title>Who benefits from an Ehealth-based stress management intervention in advanced prostate cancer? Results from a randomized controlled trial</article-title>. <source>Psychooncology</source>. (<year>2022</year>) <volume>31</volume>(<issue>12</issue>):<fpage>2063</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1002/pon.6000</pub-id><pub-id pub-id-type="pmid">35851976</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galv&#x000e3;o</surname><given-names>DA</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><name><surname>Girgis</surname><given-names>A</given-names></name><name><surname>Lepore</surname><given-names>SJ</given-names></name><name><surname>Stiller</surname><given-names>A</given-names></name><name><surname>Mihalopoulos</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Randomized controlled trial of a peer led multimodal intervention for men with prostate cancer to increase exercise participation</article-title>. <source>Psychooncology</source>. (<year>2018</year>) <volume>27</volume>(<issue>1</issue>):<fpage>199</fpage>&#x02013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1002/pon.4495</pub-id><pub-id pub-id-type="pmid">28685892</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>SD</given-names></name><name><surname>Duncan</surname><given-names>LR</given-names></name><name><surname>Culos-Reed</surname><given-names>SN</given-names></name><name><surname>Hallward</surname><given-names>L</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Loban</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Feasibility, acceptability, and clinical significance of a dyadic, web-based, psychosocial and physical activity self-management program (tempo) tailored to the needs of men with prostate cancer and their caregivers: a multi-center randomized pilot trial</article-title>. <source>Curr Oncol</source>. (<year>2022</year>) <volume>29</volume>(<issue>2</issue>):<fpage>785</fpage>&#x02013;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.3390/curroncol29020067</pub-id><pub-id pub-id-type="pmid">35200566</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>SK</given-names></name><name><surname>Occhipinti</surname><given-names>S</given-names></name><name><surname>Schover</surname><given-names>L</given-names></name><name><surname>Nielsen</surname><given-names>L</given-names></name><name><surname>Zajdlewicz</surname><given-names>L</given-names></name><name><surname>Clutton</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>A randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer and their female partners</article-title>. <source>Psychooncology</source>. (<year>2015</year>) <volume>24</volume>(<issue>7</issue>):<fpage>748</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1002/pon.3726</pub-id><pub-id pub-id-type="pmid">25483780</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>PLoS Med</source>. (<year>2009</year>) <volume>6</volume>(<issue>7</issue>):<fpage>e1000097</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id><pub-id pub-id-type="pmid">19621072</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JPT</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Chandler</surname><given-names>J</given-names></name><name><surname>Cumpston</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Page</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>Cochrane Handbook for Systematic Reviews of Interventions Version 6.4</article-title> (updated August 2023). Cochrane (<year>2023</year>). Available at: <ext-link xlink:href="https://training.cochrane.org/handbook" ext-link-type="uri">https://training.cochrane.org/handbook</ext-link> (Accessed November 08, 2024).</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giesler</surname><given-names>RB</given-names></name><name><surname>Given</surname><given-names>B</given-names></name><name><surname>Given</surname><given-names>CW</given-names></name><name><surname>Rawl</surname><given-names>S</given-names></name><name><surname>Monahan</surname><given-names>P</given-names></name><name><surname>Burns</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nurse-driven intervention</article-title>. <source>Cancer</source>. (<year>2005</year>) <volume>104</volume>(<issue>4</issue>):<fpage>752</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.21231</pub-id><pub-id pub-id-type="pmid">15986401</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>R</given-names></name><name><surname>Heller</surname><given-names>A</given-names></name><name><surname>Moreno</surname><given-names>PI</given-names></name><name><surname>Yanez</surname><given-names>B</given-names></name><name><surname>Penedo</surname><given-names>FJ</given-names></name></person-group>. <article-title>Low social well-being in advanced and metastatic prostate cancer: effects of a randomized controlled trial of cognitive behavioral stress management</article-title>. <source>Int J Behav Med</source>. (<year>2024</year>) <volume>35</volume>(<issue>14</issue>):<fpage>1</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1007/s12529-024-10270-w</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langlais</surname><given-names>CS</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Van Blarigan</surname><given-names>EL</given-names></name><name><surname>Kenfield</surname><given-names>SA</given-names></name><name><surname>Kessler</surname><given-names>ER</given-names></name><name><surname>Daniel</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Quality of life of prostate cancer survivors participating in a remotely delivered web-based behavioral intervention pilot randomized trial</article-title>. <source>Integr Cancer Ther</source>. (<year>2022</year>) <volume>21</volume>:<fpage>15347354211063500</fpage>. <pub-id pub-id-type="doi">10.1177/15347354211063500</pub-id><pub-id pub-id-type="pmid">35389288</pub-id>
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagai</surname><given-names>EK</given-names></name><name><surname>Miller</surname><given-names>SM</given-names></name><name><surname>Hudson</surname><given-names>SV</given-names></name><name><surname>Diefenbach</surname><given-names>MA</given-names></name><name><surname>Handorf</surname><given-names>E</given-names></name><name><surname>Bator</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Improved cancer coping from a web-based intervention for prostate cancer survivors: a randomized controlled trial</article-title>. <source>Psychooncology</source>. (<year>2021</year>) <volume>30</volume>(<issue>9</issue>):<fpage>1466</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1002/pon.5701</pub-id><pub-id pub-id-type="pmid">33855796</pub-id>
</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wennerberg</surname><given-names>C</given-names></name><name><surname>Hellstr&#x000f6;m</surname><given-names>A</given-names></name><name><surname>Schildmeijer</surname><given-names>K</given-names></name><name><surname>Ekstedt</surname><given-names>M</given-names></name></person-group>. <article-title>Effects of web-based and Mobile self-care support in addition to standard care in patients after radical prostatectomy: randomized controlled trial</article-title>. <source>Jmir Cancer</source>. (<year>2023</year>) <volume>9</volume>:<fpage>e44320</fpage>. <pub-id pub-id-type="doi">10.2196/44320</pub-id><pub-id pub-id-type="pmid">37672332</pub-id>
</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heydenreich</surname><given-names>M</given-names></name><name><surname>Puta</surname><given-names>C</given-names></name><name><surname>Gabriel</surname><given-names>HHW</given-names></name><name><surname>Dietze</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>P</given-names></name><name><surname>Zermann</surname><given-names>D</given-names></name></person-group>. <article-title>Does trunk muscle training with an oscillating rod improve urinary incontinence after radical prostatectomy? A prospective randomized controlled trial</article-title>. <source>Clin Rehabil</source>. (<year>2020</year>) <volume>34</volume>(<issue>3</issue>):<fpage>320</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1177/0269215519893096</pub-id><pub-id pub-id-type="pmid">31858823</pub-id>
</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aliperti</surname><given-names>L</given-names></name><name><surname>Patil</surname><given-names>D</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Filson</surname><given-names>C</given-names></name><name><surname>Crociani</surname><given-names>C</given-names></name><name><surname>Sanda</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Long-term health related quality of life in prostate cancer patients requiring radiotherapy after radical prostatectomy</article-title>. <source>J Urol</source>. (<year>2017</year>) <volume>197</volume>(<issue>4</issue>):<fpage>e360</fpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2017.02.863</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dronca</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>R</given-names></name><name><surname>Maniaci</surname><given-names>M</given-names></name><name><surname>Odedina</surname><given-names>F</given-names></name><name><surname>Kaninjing</surname><given-names>E</given-names></name><name><surname>Ashing</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Feasibility of patient-centered home care (PCHC) to reduce disparities in black men (BM) with advanced prostate cancer (CAP): an Iccare Consortium for Prostate Cancer in Black Men Project</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. (<year>2023</year>) <volume>32</volume>(<issue>1</issue>):<fpage>B046</fpage>. <pub-id pub-id-type="doi">10.1158/1538-7755.DISP22-B046</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Fuller</surname><given-names>GP</given-names></name><name><surname>Dobias</surname><given-names>CA</given-names></name><name><surname>Idiagbonya</surname><given-names>E</given-names></name><name><surname>Song</surname><given-names>L</given-names></name></person-group>. <article-title>Neighborhood deprivation and living with prostate cancer: patients&#x02019; and Partners&#x02019; psychosocial behavioral Status, symptoms, and quality of life</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. (<year>2022</year>) <volume>31</volume>(<issue>1 SUPPL</issue>):<fpage>PO-176</fpage>. <pub-id pub-id-type="doi">10.1158/1538-7755.DISP21-PO-176</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>HEL</given-names></name><name><surname>Galv&#x000e3;o</surname><given-names>DA</given-names></name><name><surname>Forbes</surname><given-names>CC</given-names></name><name><surname>Girard</surname><given-names>D</given-names></name><name><surname>Vandelanotte</surname><given-names>C</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><etal/></person-group>
<article-title>Acceptability and preliminary efficacy of a web- and telephone-based personalised exercise intervention for individuals with metastatic prostate cancer: the exerciseguide pilot randomised controlled trial</article-title>. <source>Cancers (Basel)</source>. (<year>2021</year>) <volume>13</volume>(<issue>23</issue>):<fpage>5925</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13235925</pub-id><pub-id pub-id-type="pmid">34885036</pub-id>
</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badger</surname><given-names>TA</given-names></name><name><surname>Segrin</surname><given-names>C</given-names></name><name><surname>Figueredo</surname><given-names>AJ</given-names></name><name><surname>Harrington</surname><given-names>J</given-names></name><name><surname>Sheppard</surname><given-names>K</given-names></name><name><surname>Passalacqua</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners</article-title>. <source>Qual Life Res</source>. (<year>2011</year>) <volume>20</volume>(<issue>6</issue>):<fpage>833</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1007/s11136-010-9822-2</pub-id><pub-id pub-id-type="pmid">21170682</pub-id>
</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>SK</given-names></name><name><surname>Occhipinti</surname><given-names>S</given-names></name><name><surname>Foley</surname><given-names>E</given-names></name><name><surname>Clutton</surname><given-names>S</given-names></name><name><surname>Legg</surname><given-names>M</given-names></name><name><surname>Berry</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Mindfulness-based cognitive therapy in advanced prostate cancer: a randomized controlled trial</article-title>. <source>J Clin Oncol</source>. (<year>2017</year>) <volume>35</volume>(<issue>3</issue>):<fpage>291</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2016.68.8788</pub-id><pub-id pub-id-type="pmid">27870567</pub-id>
</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>PS</given-names></name><name><surname>Johnson</surname><given-names>TM</given-names><suffix>2nd</suffix></name><name><surname>Newman</surname><given-names>DK</given-names></name><name><surname>Vaughan</surname><given-names>CP</given-names></name><name><surname>Echt</surname><given-names>KV</given-names></name><name><surname>Markland</surname><given-names>AD</given-names></name><etal/></person-group>
<article-title>Perioperative mobile telehealth program for post-prostatectomy incontinence: a randomized clinical trial</article-title>. <source>J Urol</source>. (<year>2022</year>) <volume>208</volume>(<issue>2</issue>):<fpage>379</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1097/ju.0000000000002697</pub-id><pub-id pub-id-type="pmid">35389239</pub-id>
</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>RC</given-names></name><name><surname>Nielsen</surname><given-names>ME</given-names></name><name><surname>Birken</surname><given-names>SA</given-names></name><etal/></person-group>
<article-title>Enhancing survivorship care planning for patients with localized prostate cancer using a couple-focused web-based, Mhealth program: the results of a pilot feasibility study</article-title>. <source>J Cancer Surviv</source>. (<year>2021</year>) <volume>15</volume>(<issue>1</issue>):<fpage>99</fpage>&#x02013;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1007/s11764-020-00914-7</pub-id><pub-id pub-id-type="pmid">32681304</pub-id>
</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittmann</surname><given-names>D</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Bober</surname><given-names>SL</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Daignault-Newton</surname><given-names>S</given-names></name><name><surname>Dunn</surname><given-names>RL</given-names></name><etal/></person-group>
<article-title>Truenth sexual recovery intervention for couples coping with prostate cancer: randomized controlled trial results</article-title>. <source>Cancer</source>. (<year>2022</year>) <volume>128</volume>(<issue>7</issue>):<fpage>1513</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.34076</pub-id><pub-id pub-id-type="pmid">34985771</pub-id>
</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wootten</surname><given-names>AC</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Abbott</surname><given-names>JM</given-names></name><name><surname>Chisholm</surname><given-names>K</given-names></name><name><surname>Austin</surname><given-names>DW</given-names></name><name><surname>Klein</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>An online psychological intervention can improve the sexual satisfaction of men following treatment for localized prostate cancer: outcomes of a randomised controlled trial evaluating my road ahead</article-title>. <source>Psychooncology</source>. (<year>2017</year>) <volume>26</volume>(<issue>7</issue>):<fpage>975</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1002/pon.4244</pub-id><pub-id pub-id-type="pmid">27503036</pub-id>
</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>KM</given-names></name><name><surname>Dawson</surname><given-names>D</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Red</surname><given-names>S</given-names></name><name><surname>Penek</surname><given-names>S</given-names></name><name><surname>Lynch</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Monitoring of health-related quality of life and symptoms in prostate cancer survivors: a randomized trial</article-title>. <source>J Support Oncol</source>. (<year>2013</year>) <volume>11</volume>(<issue>4</issue>):<fpage>174</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.12788/j.suponc.0013</pub-id><pub-id pub-id-type="pmid">24645337</pub-id>
</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>M</given-names></name><name><surname>Stefanopoulou</surname><given-names>E</given-names></name><name><surname>Yousaf</surname><given-names>O</given-names></name><name><surname>Grunfeld</surname><given-names>E</given-names></name></person-group>. <article-title>A randomised controlled trial of a cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (Mancan)</article-title>. <source>Psychooncology</source>. (<year>2014</year>) <volume>23</volume>:<fpage>126</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1099-1611.2014.3694</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>SD</given-names></name><name><surname>McElduff</surname><given-names>P</given-names></name><name><surname>Girgis</surname><given-names>A</given-names></name><name><surname>Levesque</surname><given-names>JV</given-names></name><name><surname>Regan</surname><given-names>TW</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>A pilot, multisite, randomized controlled trial of a self-directed coping skills training intervention for couples facing prostate cancer: accrual, retention, and data collection issues</article-title>. <source>Support Care Cancer</source>. (<year>2016</year>) <volume>24</volume>(<issue>2</issue>):<fpage>711</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-015-2833-3</pub-id><pub-id pub-id-type="pmid">26184499</pub-id>
</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>L</given-names></name><name><surname>Fink</surname><given-names>J</given-names></name><name><surname>Bleich</surname><given-names>C</given-names></name><name><surname>Graefen</surname><given-names>M</given-names></name><name><surname>Schulz</surname><given-names>H</given-names></name></person-group>. <article-title>Effectiveness, acceptance and satisfaction of guided chat groups in psychosocial aftercare for outpatients with prostate cancer after prostatectomy</article-title>. <source>Internet Interv Appl Inf Technol Mental Behav Health</source>. (<year>2017</year>) <volume>9</volume>:<fpage>57</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.invent.2017.06.001</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saengryeol</surname><given-names>P</given-names></name><name><surname>Kwangnam</surname><given-names>K</given-names></name><name><surname>Hyun Kyu</surname><given-names>A</given-names></name><name><surname>Jong Won</surname><given-names>K</given-names></name><name><surname>Gyurang</surname><given-names>M</given-names></name><name><surname>Byung Ha</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Impact of lifestyle intervention for patients with prostate cancer</article-title>. <source>Am J Health Behav</source>. (<year>2020</year>) <volume>44</volume>(<issue>1</issue>):<fpage>90</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.5993/AJHB.44.1.10</pub-id><pub-id pub-id-type="pmid">31783936</pub-id>
</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCaughan</surname><given-names>E</given-names></name><name><surname>Curran</surname><given-names>C</given-names></name><name><surname>Northouse</surname><given-names>L</given-names></name><name><surname>Parahoo</surname><given-names>K</given-names></name></person-group>. <article-title>Evaluating a psychosocial intervention for men with prostate cancer and their partners: outcomes and lessons learned from a randomized controlled trial</article-title>. <source>Appl Nurs Res</source>. (<year>2018</year>) <volume>40</volume>:<fpage>143</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.apnr.2018.01.008</pub-id><pub-id pub-id-type="pmid">29579490</pub-id>
</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>JI</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Cheong</surname><given-names>IY</given-names></name><name><surname>Hwang</surname><given-names>JH</given-names></name><name><surname>Seo</surname><given-names>SI</given-names></name><etal/></person-group>
<article-title>Internet of things-based lifestyle intervention for prostate cancer patients on androgen deprivation therapy: a prospective, multicenter, randomized trial</article-title>. <source>Am J Cancer Res</source>. (<year>2021</year>) <volume>11</volume>(<issue>11</issue>):<fpage>5496</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">34873475</pub-id>
</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qan'ir</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>L</given-names></name></person-group>. <article-title>Systematic review of technology-based interventions to improve anxiety, depression, and health-related quality of life among patients with prostate cancer</article-title>. <source>Psychooncology</source>. (<year>2019</year>) <volume>28</volume>(<issue>8</issue>):<fpage>1601</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1002/pon.5158</pub-id><pub-id pub-id-type="pmid">31222956</pub-id>
</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>C</given-names></name><name><surname>Brunckhorst</surname><given-names>O</given-names></name><name><surname>Eymech</surname><given-names>O</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Dasgupta</surname><given-names>P</given-names></name><name><surname>Ahmed</surname><given-names>K</given-names></name></person-group>. <article-title>Fear of cancer recurrence and PSA anxiety in patients with prostate cancer: a systematic review</article-title>. <source>Support Care Cancer</source>. (<year>2022</year>) <volume>30</volume>(<issue>7</issue>):<fpage>5577</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-022-06876-z</pub-id><pub-id pub-id-type="pmid">35106656</pub-id>
</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meissner</surname><given-names>VH</given-names></name><name><surname>Peter</surname><given-names>C</given-names></name><name><surname>Ankerst</surname><given-names>DP</given-names></name><name><surname>Schiele</surname><given-names>S</given-names></name><name><surname>Gschwend</surname><given-names>JE</given-names></name><name><surname>Herkommer</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Prostate cancer-related anxiety among long-term survivors after radical prostatectomy: a longitudinal study</article-title>. <source>Cancer Med</source>. (<year>2023</year>) <volume>12</volume>(<issue>4</issue>):<fpage>4842</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1002/cam4.5304</pub-id><pub-id pub-id-type="pmid">36254563</pub-id>
</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>S</given-names></name><name><surname>Leydon</surname><given-names>G</given-names></name><name><surname>Birch</surname><given-names>B</given-names></name><name><surname>Prescott</surname><given-names>P</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Eardley</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates</article-title>. <source>BMJ Open</source>. (<year>2014</year>) <volume>4</volume>(<issue>3</issue>):<fpage>e003901</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2013-003901</pub-id><pub-id pub-id-type="pmid">24625637</pub-id>
</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group>. <article-title>Effects of social support, hope and resilience on depressive symptoms within 18 months after diagnosis of prostate cancer</article-title>. <source>Health Qual Life Outcomes</source>. (<year>2021</year>) <volume>19</volume>(<issue>1</issue>):<fpage>15</fpage>. <pub-id pub-id-type="doi">10.1186/s12955-020-01660-1</pub-id><pub-id pub-id-type="pmid">33413485</pub-id>
</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilie</surname><given-names>G</given-names></name><name><surname>Rendon</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>R</given-names></name><name><surname>MacDonald</surname><given-names>C</given-names></name><name><surname>Kucharczyk</surname><given-names>MJ</given-names></name><name><surname>Patil</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>A comprehensive 6-Mo prostate cancer patient empowerment program decreases psychological distress among men undergoing curative prostate cancer treatment: a randomized clinical trial</article-title>. <source>Eur Urol</source>. (<year>2023</year>) <volume>83</volume>(<issue>6</issue>):<fpage>561</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2023.02.009</pub-id><pub-id pub-id-type="pmid">36822969</pub-id>
</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Occhipinti</surname><given-names>S</given-names></name><name><surname>Zajdlewicz</surname><given-names>L</given-names></name><name><surname>Coughlin</surname><given-names>GD</given-names></name><name><surname>Yaxley</surname><given-names>JW</given-names></name><name><surname>Dunglison</surname><given-names>N</given-names></name><name><surname>Gardiner</surname><given-names>RA</given-names></name><etal/></person-group>
<article-title>A prospective study of psychological distress after prostate cancer surgery</article-title>. <source>Psychooncology</source>. (<year>2019</year>) <volume>28</volume>(<issue>12</issue>):<fpage>2389</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1002/pon.5263</pub-id><pub-id pub-id-type="pmid">31659807</pub-id>
</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penedo</surname><given-names>FJ</given-names></name><name><surname>Oswald</surname><given-names>LB</given-names></name><name><surname>Kronenfeld</surname><given-names>JP</given-names></name><name><surname>Garcia</surname><given-names>SF</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Yanez</surname><given-names>B</given-names></name></person-group>. <article-title>The increasing value of Ehealth in the delivery of patient-centred cancer care</article-title>. <source>Lancet Oncol</source>. (<year>2020</year>) <volume>21</volume>(<issue>5</issue>):<fpage>e240</fpage>&#x02013;<lpage>e51</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(20)30021-8</pub-id><pub-id pub-id-type="pmid">32359500</pub-id>
</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tayama</surname><given-names>J</given-names></name><name><surname>Hamaguchi</surname><given-names>T</given-names></name><name><surname>Koizumi</surname><given-names>K</given-names></name><name><surname>Yamamura</surname><given-names>R</given-names></name><name><surname>Okubo</surname><given-names>R</given-names></name><name><surname>Kawahara</surname><given-names>JI</given-names></name><etal/></person-group>
<article-title>Efficacy of an Ehealth self-management program in reducing irritable bowel syndrome symptom severity: a randomized controlled trial</article-title>. <source>Sci Rep</source>. (<year>2024</year>) <volume>14</volume>(<issue>1</issue>):<fpage>4</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-023-50293-z</pub-id><pub-id pub-id-type="pmid">38172498</pub-id>
</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowles</surname><given-names>SR</given-names></name><name><surname>Mikocka-Walus</surname><given-names>A</given-names></name></person-group>. <article-title>Utilization and efficacy of internet-based Ehealth technology in gastroenterology: a systematic review</article-title>. <source>Scand J Gastroenterol</source>. (<year>2014</year>) <volume>49</volume>(<issue>4</issue>):<fpage>387</fpage>&#x02013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.3109/00365521.2013.865259</pub-id><pub-id pub-id-type="pmid">24494974</pub-id>
</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><collab>WHOQOL Group</collab>. <article-title>Development of the World Health Organization WHOQOL-BREF quality of life assessment</article-title>. <source>Psychol Med</source>. (<year>1998</year>) <volume>28</volume>(<issue>3</issue>):<fpage>551</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">9626712</pub-id>
</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buneviciene</surname><given-names>I</given-names></name><name><surname>Mekary</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>TR</given-names></name><name><surname>Onnela</surname><given-names>JP</given-names></name><name><surname>Bunevicius</surname><given-names>A</given-names></name></person-group>. <article-title>Can Mhealth interventions improve quality of life of cancer patients? A systematic review and meta-analysis</article-title>. <source>Crit Rev Oncol Hematol</source>. (<year>2021</year>) <volume>157</volume>:<fpage>103123</fpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2020.103123</pub-id><pub-id pub-id-type="pmid">33190065</pub-id>
</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>CR</given-names></name><name><surname>Hudson</surname><given-names>SV</given-names></name><name><surname>Diefenbach</surname><given-names>MA</given-names></name><name><surname>Wiseman</surname><given-names>KP</given-names></name><name><surname>Sanders</surname><given-names>A</given-names></name><name><surname>Coa</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Cancer health self-efficacy improvement in a randomized controlled trial</article-title>. <source>Cancer</source>. (<year>2022</year>) <volume>128</volume>(<issue>3</issue>):<fpage>597</fpage>&#x02013;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.33947</pub-id><pub-id pub-id-type="pmid">34668569</pub-id>
</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>SR</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Armany</surname><given-names>D</given-names></name><name><surname>Occhipinti</surname><given-names>S</given-names></name><name><surname>Chambers</surname><given-names>S</given-names></name><name><surname>Leslie</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Ehealth literacy in prostate cancer: a systematic review</article-title>. <source>Patient Educ Couns</source>. (<year>2024</year>) <volume>123</volume>:<fpage>108193</fpage>. <pub-id pub-id-type="doi">10.1016/j.pec.2024.108193</pub-id><pub-id pub-id-type="pmid">38354430</pub-id>
</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>DD</given-names></name><name><surname>Robinson</surname><given-names>K</given-names></name><name><surname>Forbes</surname><given-names>J</given-names></name><name><surname>Hayes</surname><given-names>S</given-names></name></person-group>. <article-title>Experiences of mobile health in promoting physical activity: a qualitative systematic review and meta-ethnography</article-title>. <source>PLoS One</source>. (<year>2018</year>) <volume>13</volume>(<issue>12</issue>):<fpage>e0208759</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0208759</pub-id><pub-id pub-id-type="pmid">30557396</pub-id>
</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group>. <article-title>Application of mobile internet management in the continuing care of patients after radical prostatectomy</article-title>. <source>Sci Rep</source>. (<year>2024</year>) <volume>14</volume>(<issue>1</issue>):<fpage>31520</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-024-83303-9</pub-id><pub-id pub-id-type="pmid">39733026</pub-id>
</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>LS</given-names></name><name><surname>Keefe</surname><given-names>FJ</given-names></name><name><surname>Garst</surname><given-names>J</given-names></name><name><surname>Baucom</surname><given-names>DH</given-names></name><name><surname>McBride</surname><given-names>CM</given-names></name><name><surname>McKee</surname><given-names>DC</given-names></name><etal/></person-group>
<article-title>Caregiver-assisted coping skills training for lung cancer: results of a randomized clinical trial</article-title>. <source>J Pain Symptom Manage</source>. (<year>2011</year>) <volume>41</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpainsymman.2010.04.014</pub-id><pub-id pub-id-type="pmid">20832982</pub-id>
</mixed-citation></ref></ref-list></back></article>